MTOR and glioblastoma: Four mTOR inhibitors that are under clinical investigation for oncologic conditions located in the head and brain showed micromolar EC50 against two or three free-living amebae (sapanisertib in glioblastoma (NCT02133183), GDC-0084 in brain metastasis (NCT03765983), PF-04691502 and bimiralisib in Head and Neck Squamous Cell Carcinoma (NCT03740100; Tonlaar et al., 2017).